The next big AI market may be hiding between the doctor and the pharmacy
A doctor writes a prescription.
That should be the easy part.
Instead, patients can get stuck between insurers, pharmacies, financial-assistance programs and layers of paperwork before they ever receive the drug.
Forus was built around that mess.
The healthcare automation startup just raised $150 million at a $3 billion valuation, only months after its previous financing. Bain Capital Ventures led the round alongside Accel, Thrive Capital, General Catalyst, Redpoint Ventures and others.
Founded in 2023, Forus uses AI to manage the steps that begin after a prescription is written: insurance coverage, financial assistance, pharmacy coordination and other administrative work that can delay access to medication.
We find the model interesting because it points toward a part of AI healthcare that could scale faster than some of the more ambitious clinical applications.
Forus isn’t trying to replace the doctor.
It is trying to remove everything slowing the doctor down.
Healthcare has exactly the kind of problem AI is good at solving
Healthcare is full of repetitive, expensive workflows involving documents, phone calls, eligibility checks and large amounts of fragmented data.
That is fertile ground for automation.
Forus says its platform learns from millions of cases and is free for providers and patients. The company sits in the middle of the process, where shaving days off prescription access can create value without asking hospitals to completely redesign how medicine is practiced.
The investment money is following.
Forus is not alone. Latent raised $80 million in March, while Courier Health secured $50 million in April. Capital is clearly moving toward companies using AI to attack the administrative side of healthcare.
And that may be the first real wave.
AI is moving quickly into industries most people aren’t watching yet. Get our latest research and new ideas straight to your inbox →
The market opportunity goes far beyond one startup
The healthcare AI story is often framed around futuristic diagnostics, drug discovery or machines making clinical decisions.
Those areas could become enormous.
But they also face tougher regulatory, liability and adoption hurdles.
Administrative automation has a simpler pitch: save time, reduce labor and get patients through the system faster.
Hospitals, insurers, pharmacies and drug companies already spend enormous amounts managing those processes. An AI platform does not need to invent a new treatment to justify its existence. It can create value simply by making the existing healthcare system less inefficient.
That creates opportunities across several areas:
- Prescription and insurance automation
- Clinical documentation
- Billing and revenue-cycle management
- Patient scheduling and communication
- Prior authorization
- Pharmacy and provider workflow software
The companies that own these workflows may become some of the most interesting AI businesses in healthcare because they can prove the return on investment quickly.
A $3 billion valuation this early tells us where capital is looking
Forus is only three years old.
Reaching a $3 billion valuation this quickly tells us investors are not treating healthcare automation as a niche experiment.
Bain Capital partner Kevin Zhang described Forus as one of the fastest-growing companies across the firm’s portfolio.
That doesn’t guarantee the valuation holds. Private AI markets are competitive, and plenty of companies will claim they can automate healthcare before proving they can build a durable business.
The more important signal is where sophisticated capital keeps showing up.
AI infrastructure attracted the first giant wave of money. Then came enterprise software. Healthcare increasingly looks like one of the next major battlegrounds.
We’re also digging into an underfollowed AI healthcare company that hasn’t attracted this kind of attention yet. Join the WSA newsletter to see what we’re watching →
The companies worth watching may already own the workflow
Our attention isn’t limited to the startups raising venture rounds.
Public companies already embedded inside hospitals, insurers, pharmacies and physician practices could have an enormous distribution advantage if they successfully layer AI into products customers already use.
The strongest setup may not be the company with the flashiest model.
It may be the company sitting on the right data, inside the right workflow, with customers already paying for the software.
Forus offers a glimpse of where the market is heading.
AI does not need to cure cancer tomorrow to transform healthcare.
There is already billions of dollars of friction sitting between patients and the care they are supposed to receive.
Removing that friction may become one of AI’s biggest businesses.
Explore More Stories in Health
Disclaimer
Wall Street Access is an independent financial publisher. Wall Street Access is not a financial advisor. No company mentioned has compensated Wall Street Access for the preparation, publication or distribution of this article. This content is provided for informational and educational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Investing involves risk, including the possible loss of principal.
Prices, market capitalizations, financial figures and other market data are based on information available as of the date and time of publication and may change without notice. Information is drawn from public sources believed to be reliable but is not guaranteed to be complete or accurate. Opinions and expectations expressed are our own and may change as new information becomes available.
Readers should conduct their own due diligence and contact a licensed financial professional before making any investment decision. Past performance does not guarantee future results. Any material ownership interest or conflict of interest, where applicable, will be disclosed separately.
